FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Comments Sought on Study Design for Heartworm Drugs

Federal Register notice: FDA seeks comments as it evaluates current thinking about the design of studies intended to generate data to support investig...

Federal Register

Info Collection Extension for PDMA Policies, Requirements

Federal Register notice: FDA submits to OMB for approval an information collection extension for Prescription Drug Marketing Act of 1987 Administrati...

Human Drugs

FDA Clears Cotinga Cancer Trial Amendment

FDA clears a protocol amendment to expand the Phase 1b/2a clinical trial of Cotingas COTI-2 to evaluate additional cancers as a combination therapy.

Human Drugs

Pine Pharmaceuticals FDA-483 Released

FDA releases the FDA-483 with three observations from an inspection at Pine Pharmaceuticals.

Human Drugs

MUsT Guidance Helps OTC Studies

CDER director of nonprescription drug products director Theresa Michele says the agency has issued a guidance on maximal usage studies to help OTC dru...

Human Drugs

FDA Seeks Withdrawal of Benzocaine Teething Products

FDA asks manufacturers of OTC teething aids containing benzocaine to pull them from the market or face regulatory action to force them out.

Human Drugs

Anthrax Drug Development Guidance

FDA issues a guidance on developing drugs with an indication of prophylaxis to inhalational anthrax in certain persons.

Human Drugs

U.S. Asks Supreme Court to Hear Fosamax Case

The Solicitor General tells the Supreme Court the government believes the court should hear Mercks appeal of a Fosmax failure-to-warn case.

Federal Register

Guide on OTC Sunscreen Enforcement Policy

Federal Register notice: FDA makes available a guidance entitled Enforcement Policy OTC Sunscreen Drug Products Marketed Without an Approved Applicat...

Federal Register

Guide on OTC Maximal Usage Drug Trials

Federal Register notice: FDA makes available a draft guidance for industry entitled Maximal Usage Trials for Topical Active Ingredients Being Consider...